INGA:EURONEXT AMSTERDAM
ING Groep N.V.
Data as of 2026-03-10 - not real-time
€22.55
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
ING Groep N.V. trades at a trailing P/E of roughly 10.6, well below the industry average of 17.4, indicating a clear valuation discount. The bank delivers a robust 4.79% dividend yield with a modest 50% payout ratio, suggesting the dividend is financially sustainable. Recent earnings guidance upgrades and a sizable €1.1 billion share‑buyback programme provide additional upside catalysts, while the redemption of senior notes improves the balance‑sheet risk profile. Operating margins remain healthy at around 63% and return on equity sits near 15.8%, underscoring solid profitability despite a slight negative operating cash flow.
On the technical side, the stock is hovering just above its identified support of €21.80 and below the 20‑day SMA, with an RSI of 33 signaling oversold conditions. The MACD histogram is negative, indicating short‑term bearish momentum, yet the overall trend is neutral and volume is increasing, reflecting growing investor interest. Low beta (0.39) and a 30‑day volatility of about 31% point to moderate price swings, while the outlook is buoyed by a median analyst price target of €28, implying roughly a 20% upside.
On the technical side, the stock is hovering just above its identified support of €21.80 and below the 20‑day SMA, with an RSI of 33 signaling oversold conditions. The MACD histogram is negative, indicating short‑term bearish momentum, yet the overall trend is neutral and volume is increasing, reflecting growing investor interest. Low beta (0.39) and a 30‑day volatility of about 31% point to moderate price swings, while the outlook is buoyed by a median analyst price target of €28, implying roughly a 20% upside.
Trading Recommendations
Short Term
< 1 yearbuy
Conviction: 7/10
Key Factors
- Oversold RSI suggesting near‑term price rebound
- Proximity to strong support level
- Recent share‑buyback activity boosting demand
Medium Term
1–3 yearsbuy
Conviction: 8/10
Key Factors
- Attractive valuation relative to peers
- High dividend yield with sustainable payout
- Analyst price targets indicating ~20% upside
Long Term
> 3 yearshold
Conviction: 6/10
Key Factors
- Regulatory environment for banks may constrain growth
- Consistent dividend and low beta support stability
- Balance‑sheet improvements from debt redemptions
Key Metrics & Analysis
Financial Health
Revenue Growth118.20%
Profit Margin34.03%
P/E Ratio10.6
ROE15.77%
ROA0.83%
P/B Ratio1.2
Op. Cash Flow€-43684999168
Industry P/E17.4
Technical Analysis
TrendNeutral
RSI33.5
Support€21.80
Resistance€26.38
MA 20€24.27
MA 50€24.54
MA 200€21.77
MACDBearish
VolumeIncreasing
Fear & Greed Index75.89
Valuation
Target Price€26.94
Upside/Downside19.45%
GradeUndervalued
TypeValue
Dividend Yield4.79%
Risk Assessment
Beta0.39
Volatility30.82%
Sector RiskMedium
Reg. RiskHigh
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
More Tickers
This analysis may contain inaccuracies. Not financial advice. Always do your own research before making any investment decisions.